2 recruiting, 1 completed, 1 not yet recruiting. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Recruiting 2, Completed 1, Not yet recruiting 1 |
Follow Sickle Cell Disease (SCD): new trials by email Literature Review of Sickle Cell Disease (SCD) trials Research Report on Sickle Cell Disease (SCD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm) - Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD) | Phase 4 | Not yet recruiting | University of Mississippi Medical Center | 400 | 2026-08-01 | 2026-07-06 |
| Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire Gazelle-Multispectral point of care testing for newborn sickle cell disease screening; and initiation of early comprehensive clinical interventions - Sickle Cell Disease (SCD) | Phase 4 | Recruiting | Swiss Tropical & Public Health Institute | 120 | 2026-07-27 | 2026-10-05 |
| Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease Depot medroxyprogesterone acetate (DMPA) - Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 4 | Recruiting | University of Pennsylvania | 65 | 2025-06-26 | 2026-11-05 |
| An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients crizanlizumab - Sickle Cell Disease (SCD) | Phase 4 | Completed | Novartis Pharmaceuticals | 140 | 2021-07-14 | 2025-09-26 |
Anemia, Sickle Cell (4) · Hemoglobin SC Disease (1) · Vaso-Occlusive Crises (1)
Anemia (4) · Anemia, Hemolytic (4) · Anemia, Hemolytic, Congenital (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Hemoglobinopathies (4)
Health Services Needs and Demand (1) · Standard of Care (1) · crizanlizumab (1)
Novartis Pharmaceuticals (1) · Swiss Tropical & Public Health Institute (1) · University of Mississippi Medical Center (1) · University of Pennsylvania (1)
United States (2) · Côte d’Ivoire (1) · India (1)
Andrea Roe, MD MPH (1) · John N Freeman, MD (1)
R01HL175726 (1)